HC Wainwright Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR)

HC Wainwright reiterated their buy rating on shares of Vir Biotechnology (NASDAQ:VIR – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $110.00 target price on the stock. Several other research firms have also issued reports on VIR. Barclays lowered their target price on shares of […]

Leave a Reply

Your email address will not be published.

Previous post Strategy Asset Managers LLC Takes $702,000 Position in The Williams Companies, Inc. (NYSE:WMB)
Next post Segall Bryant & Hamill LLC Buys New Shares in Fidelity Low Volatility Factor ETF (NYSEARCA:FDLO)